Prodose Inc. Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Prodose Inc. Pharmaceutical Import Records from India — 5 Products, $4.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Prodose Inc. — Pharmaceutical Importer Profile (2026) | 5 Products, $4.0M Trade | TransData Nexus

Prodose Inc.

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $4.0M Total Trade · DGFT Verified

Prodose Inc. is a pharmaceutical importer based in United States with a total trade value of $4.0M across 5 products in 3 therapeutic categories. Based on 79 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Prodose Inc. sources from 1 verified Indian supplier, with Elysium Pharmaceuticals Limited accounting for 100.0% of imports.

Prodose Inc. — Import Portfolio & Supplier Network

Prodose Inc. import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Prodose Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Elysium Pharmaceuticals Limited	$1.9M	48	100.0%

Prodose Inc. sources from 1 verified Indian supplier across 38 distinct formulations. The sourcing is highly concentrated — Elysium Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Prodose Inc. Import?

Formulation	Value	Ships
Acetaminophen dextromethorphan hydrobromide doxylamine succinate &phenylephrinehcl capsule-907(anne.a dtls asper	$100.0K	2
Acetaminophen tabs USP 500MG (annexure-a dtls as per invoice & pck list)	$100.0K	2
Aspirin delayed release tablets USP 81MG (annexure - c) as per	$100.0K	2
Acetaminophen TAB's USP 500MG (annexure - b) as per	$100.0K	2
Diphenhydramine hcl tablets USP 25MG - blue (annexure - d) as per	$100.0K	2
Acetaminophen dextromethorphan hydrobromide and phenylephrine hcl capsules-915(annexure-b (dtls asper inv.pck)	$83.1K	2
Acetaminophen dextromethorphen hydrobromide and doxylamine succinate capsules-902 ,dtls as per invoice & annexure -a)	$81.8K	2
Acetaminophen guaifenesin dextromethorphan hydrobromide and phenylephrine hcl capsules-913(anne-c(dtls asper	$63.9K	2
Acetaminophen and caffeine tablets USP-s431 -151(anne-c(dtls asper	$57.6K	2
Acetaminophen dextromethorphen hydrobromide and phenyleprine hcl capsule -915,dtls as per invoice & annexure -a)	$50.0K	1
Acetaminophen dextromethorphen hydrobromide,doxylamine succinate&phenylephrine hcl capsule-907,dtls asper	$50.0K	1
Guaifenesin and dextromethorphan hbr capsules (200/10)-905 ,dtls asper	$50.0K	1
Acetaminophen guaifenesin dextromethorphan hydrobromide & phenylephrine hcl capsule-913 ,dtls as per inv.& annexure	$50.0K	1
Aacetaminophen diphenhydramine hcl tablets (s525)-11282 (dtls as per invoice & annexure -a)	$50.0K	1
Acetaminophen dextromethorphen hydrobromide, doxylamine succinate & phenylephrine hcl	$50.0K	1

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetaminophen	Analgesics & Antipyretics	$1.9M	37	0.8%	14
2	Phenylephrine	Respiratory & OTC	$800.0K	16	0.9%	19
3	Dextromethorphan	Respiratory & OTC	$500.0K	10	3.4%	2
4	Guaifenesin	Respiratory & OTC	$500.0K	10	1.9%	7
5	Diphenhydramine	Antihistamines & Allergy	$300.0K	6	0.9%	12

Prodose Inc. imports 5 pharmaceutical products across 3 categories into United States totaling $4.0M.

Prodose Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Prodose Inc. is a privately held pharmaceutical company headquartered in Ronkonkoma, New York. Established in 2003 as Spirit Pharmaceuticals LLC, the company specializes in the manufacturing, marketing, and distribution of over-the-counter (OTC) drug products, focusing primarily on private-label store brands. Serving a diverse clientele across drug, food, mass, and club channels, Prodose is recognized for its innovation, competitive advantage, and commitment to reliable service.

The company operates a state-of-the-art facility in Ronkonkoma, New York, spanning over 106,000 square feet. This facility is equipped with advanced packaging and distribution capabilities, ensuring high-quality production standards. In 2025, Prodose expanded its manufacturing footprint by enhancing its New York facility, scaling up to approximately 115,000 square feet, aiming to boost production capacity and improve supply chain efficiency for its growing OTC and nutraceutical portfolio.

2Distribution Network

Prodose Inc. maintains a robust distribution network within the United States, centered around its expansive facility in Ronkonkoma, New York. This strategic location facilitates efficient logistics and timely delivery of products to various retailers across the country. The company's dual-site model combines high-efficiency production in India with U.S.-based final-mile packaging and distribution, providing cost-effective volume and market-ready quality.

3Industry Role

In the United States pharmaceutical supply chain, Prodose Inc. functions as a primary wholesaler and distributor of over-the-counter (OTC) drug products. By specializing in private-label store brands, the company serves as a key intermediary between manufacturers and retailers, ensuring the availability of a diverse range of OTC medications and health products to meet consumer demand.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Prodose Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Prodose Inc. exhibits a high degree of sourcing concentration, importing 100% of its finished pharmaceutical formulations from a single supplier, Elysium Pharmaceuticals Limited. This exclusive sourcing strategy may present risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments—48 recorded between 2022 and 2026—suggests a stable and reliable relationship between Prodose and Elysium Pharmaceuticals Limited.

2Supply Chain Resilience

The resilience of Prodose Inc.'s supply chain is closely tied to its exclusive partnership with Elysium Pharmaceuticals Limited. While this singular sourcing approach may expose the company to risks associated with supply chain disruptions, the long-standing and consistent nature of the relationship indicates a level of stability. The dual-site model, combining high-efficiency production in India with U.S.-based final-mile packaging and distribution, further enhances supply chain resilience by mitigating potential disruptions and ensuring timely delivery.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug registration, listing, and compliance with manufacturing standards. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for ensuring that imported drugs meet the same standards for quality, safety, and effectiveness as those produced domestically.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States mandate that all drugs, including those imported from India, be registered with the FDA. Manufacturers must comply with Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal list of recognized GMP certifications, compliance with internationally accepted standards, such as those from the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), is generally considered acceptable. Additionally, importers must obtain a wholesale distribution authorization to legally distribute pharmaceutical products within the U.S. market.

Prodose Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Prodose Inc. focuses on importing finished pharmaceutical formulations in the therapeutic categories of Analgesics & Antipyretics, Respiratory & OTC, and Antihistamines & Allergy. This strategic focus aligns with market demand for common OTC medications used to treat pain, cold symptoms, and allergies. The company's portfolio includes top-selling products such as Acetaminophen, Phenylephrine, Dextromethorphan, Guaifenesin, and Diphenhydramine, indicating a targeted approach to meet consumer needs in these prevalent health areas.

2Sourcing Profile

Prodose Inc. employs a sourcing strategy that relies heavily on a single supplier, Elysium Pharmaceuticals Limited, for its finished pharmaceutical formulations. This approach allows for streamlined procurement processes and potentially favorable terms due to the volume of business. However, it also introduces risks associated with supply chain disruptions. India's established pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a strategic fit for Prodose's procurement needs.

3Market Positioning

Based on its product mix, Prodose Inc. serves the retail pharmacy segment of the United States market. By providing a range of OTC medications and health products, the company ensures that retailers have access to essential consumer health products, thereby supporting the retail pharmacy sector in meeting consumer demand for over-the-counter solutions.

Seller's Guide — How to Become a Supplier to Prodose Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Prodose Inc., especially if they can demonstrate compliance with FDA regulations, consistent product quality, and reliable supply capabilities. Diversifying Prodose's supplier base could enhance supply chain resilience and mitigate risks associated with sole sourcing. Potential gaps in Prodose's current sourcing include the need for alternative suppliers who can meet the company's quality standards and delivery timelines.

2Requirements & Qualifications

Indian exporters seeking to supply Prodose Inc. and the U.S. market must ensure compliance with FDA regulations, including obtaining necessary import licenses and adhering to GMP standards recognized by the FDA. Products must undergo batch testing and meet stability requirements. Labeling must be in English and comply with FDA standards. Additionally, exporters should be prepared to provide detailed documentation regarding their manufacturing processes and quality control measures to facilitate FDA approval.

3How to Approach

Frequently Asked Questions — Prodose Inc.

What products does Prodose Inc. import from India?

Prodose Inc. imports 5 pharmaceutical products across 3 categories. Top imports: Acetaminophen ($1.9M), Phenylephrine ($800.0K), Dextromethorphan ($500.0K), Guaifenesin ($500.0K), Diphenhydramine ($300.0K).

Who supplies pharmaceuticals to Prodose Inc. from India?

Prodose Inc. sources from 1 verified Indian suppliers. The primary supplier is Elysium Pharmaceuticals Limited (100.0% of imports, $1.9M).

What is Prodose Inc.'s total pharmaceutical import value?

Prodose Inc.'s total pharmaceutical import value from India is $4.0M, based on 79 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Prodose Inc. focus on?

Prodose Inc. imports across 3 categories. The largest: Analgesics & Antipyretics (46.8%), Respiratory & OTC (45.6%), Antihistamines & Allergy (7.6%).

Get Full Prodose Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.